Clinical Trial Update: Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis [Phase 2]

View source ↗

Summary

Open-label Phase 2 study evaluating enzalutamide with Radium-223 dichloride in castration-resistant prostate cancer with symptomatic bone metastases has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Prostate Carcinoma Metastatic to the Bone

Drugs mentioned

• Enzalutamide (enzalutamide)
• Radium Ra-223 Dichloride (radium-223 dichloride)

Snippet

Sponsor: Carolina Research Professionals, LLC | Conditions: Prostate Carcinoma Metastatic to the Bone | Phase 2 | Status: COMPLETED